A Phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis

Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: Week 28 interim analysis of a Phase 4 study

Cardiovascular events, serious infections, and neoplasia through 5 years of tildrakizumab exposure in 2 Phase 3 clinical trials

Tildrakizumab efficacy and safety in patients with psoriatic arthritis by metabolic syndrome status

Evaluation of teledermatology during a pandemic indicates high patient satisfaction, positive impact on patient-related costs and clinical effectiveness

What’s the low down on Biologics and MACE? A systemic review and meta-analysis

Dual biologic therapy with Omalizumab and Dupilumab for refractory atopic disease

Real-world evidence of Guselkumab for the treatment of moderate-to-severe psoriasis: Efficacy and drug survival analysis from the Australasian Psoriasis Registry

Tildrakizumab for the treatment of refractory granulomatous cheilitis

A co-designed national program with dermatologists and patients to support quality use of medicines for biologics and other specialised medicines in plaque psoriasis